Sometimes you have to sell a few things to focus on what really matters. That's the story with Surgery Partners (SGRY) today, as the surgical services provider announced it's selling its stakes in two Idaho hospitals for a cool $795 million.
The buyer is Intermountain Health, and the deal covers Surgery Partners' ownership interests in Mountain View Hospital and Idaho Falls Community Hospital. The total valuation of those facilities clocks in at about $1.15 billion, so the company is monetizing a significant chunk of its Idaho presence.
CEO Eric Evans framed the move as a strategic pivot, not a retreat. "For Surgery Partners, assuming physician partner approval, this transaction represents the largest step forward in our portfolio optimization strategy to date, simplifying our go-forward operations, and positioning us to accelerate momentum in the rapidly growing, high-value ambulatory surgery center space," he said.
In plain English: Surgery Partners is cashing out of some traditional hospital assets to pour more resources into the faster-growing, higher-margin ambulatory surgery center (ASC) business. ASCs are outpatient facilities where patients can have procedures done without an overnight stay — think knee replacements, cataract surgery, and the like. It's a hot area in healthcare right now, as insurers and patients alike push for cheaper, more convenient alternatives to hospital stays.
The company also reaffirmed its fiscal 2026 outlook, projecting revenues between $3.35 billion and $3.45 billion (the consensus is $3.408 billion) and adjusted EBITDA of at least $530 million. That's a vote of confidence that the Idaho sale won't leave a gaping hole in the income statement.
What the Charts Say
Investors liked the news. SGRY shares were up 6.31% at $16.18 on Friday afternoon. But the stock has had a rough year — it hit a 52-week low recently, and the technical picture is mixed.
The stock is trading just 1.1% below its 20-day simple moving average of $16.26, which is a mildly bullish signal. But the 50-day SMA sits 7.5% above the current price, which could act as a ceiling. The Relative Strength Index (RSI) is at 53.11 — right in the middle of the neutral zone, meaning the stock isn't overbought or oversold. That leaves room for more upside if the bulls can push through resistance.
Key levels to watch: resistance at $16.50, where rallies have stalled before, and support at $13.50, where buyers have stepped in historically.
Earnings on the Horizon
Surgery Partners is scheduled to report its next quarterly results on August 10, 2026. Analysts are expecting earnings per share of just 4 cents, down from 17 cents in the same quarter last year. Revenue is expected to tick up to $831.33 million from $826.20 million. So the bar is low on the profit side, but the top line is still growing modestly.
Value, Growth, and Momentum: The Scorecard
MarketDash's Edge scorecard gives Surgery Partners a mixed report card. On value, it scores a weak 11.41 — the stock is trading at a steep premium compared to peers. Growth scores a 4.31, also weak, reflecting limited near-term expansion. Momentum is similarly weak at 18.2, meaning the stock has been underperforming the broader market. The Idaho sale could help change that narrative, but the scorecard suggests investors are still waiting for proof.
For now, the market is giving Surgery Partners the benefit of the doubt. The stock is up, the deal is done (pending physician partner approval), and the company has a clearer path forward. Whether that path leads to higher valuations is a question for the next few quarters.
